September 2026 in “Journal of Periodontal Research”
In this narrative review, the authors found epidemiological evidence suggesting a positive link between periodontitis and psoriasis, with treatment for periodontitis potentially reducing psoriasis severity over the short term, though causality and mechanisms remain unclear.
April 2023 in “Journal of Investigative Dermatology”
This study found that while nicotinic acid significantly inhibited human sebaceous organoid growth in vitro, the predicted skin concentrations from gut microbiome-derived levels were far below the effective dose, suggesting high oral doses would be necessary for therapeutic effects.
6 citations
,
May 2022 in “Colloids and Surfaces B: Biointerfaces”
This study found that oral administration of naturally safe active polypeptides from marine shellfish promoted scarless dermal wound healing in mice, potentially via effects on inflammation, fibroblast activity, and the "skin-gut" axis.
157 citations
,
December 2015 in “Journal of the American Academy of Dermatology”
This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.
Topical roflumilast is effective for reducing inflammation in various scalp conditions like seborrheic dermatitis, psoriasis, and eczema, but not proven to stop scarring alopecia. Alternatives like apremilast and Vtama are also discussed for their anti-inflammatory benefits.
There is skepticism about new hair loss treatments, with the belief that current options like minoxidil, finasteride, and hair transplants are the best available. Concerns are raised about the systemic side effects of androgen-related treatments, even those marketed as topical, and doubts about the effectiveness of emerging treatments like clascoterone.
KX826 is considered a legitimate option for those who cannot use finasteride or dutasteride, but many users report it as ineffective compared to RU58841. RU58841 is favored by some due to anecdotal evidence of effectiveness, despite the lack of published clinical data.
A 24-year-old male experienced side effects like low libido and ED after starting finasteride post-hair transplant and is seeking alternatives to reduce scalp DHT. Suggestions include topical finasteride, Xpecia, DHT-reducing shampoos, and switching to dutasteride, with some users reporting fewer side effects with these alternatives.
The treatment for androgenetic alopecia involves using finasteride and minoxidil with intense exercise and cold exposure to boost metabolism and reduce androgenic effects, potentially leading to hair regrowth. This approach may activate biological pathways for improved hair and overall health.
How does topical Estradiol compare to oral Estradiol in treating alopecia?No study has compared topical and oral estradiol for hair loss, and estradiol applied to skin is still absorbed into the blood. Either form needs a doctor's supervision, and people with estrogen-sensitive cancers must not use it without medical approval.
GHK-Cu: Does it have side effects or is it completely safe?For topical cosmetic use, one 24-hour study in cultured skin cells found a low potential for irritation, but no clinical trial has characterised its side effects on the scalp. Injected or oral GHK-Cu has no published human safety data, and the FDA lists injectable GHK-Cu among compounding substances that may present significant safety risks.